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Abstract
Background
Hypersensitivity reaction to abacavir is strongly associated with the presence of the 
HLA-B*5701 allele. This study was designed to establish the effectiveness of prospec-
tive HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.
Methods
This double-blind, prospective, randomized study involved 1956 patients from 19 coun-
tries, who were infected with human immunodeficiency virus type 1 and who had 
not previously received abacavir. We randomly assigned patients to undergo prospec-
tive HLA-B*5701 screening, with exclusion of HLA-B*5701–positive patients from aba-
cavir treatment (prospective-screening group), or to undergo a standard-of-care ap-
proach of abacavir use without prospective HLA-B*5701 screening (control group). All 
patients who started abacavir were observed for 6 weeks. To immunologically con-
firm, and enhance the specificity of, the clinical diagnosis of hypersensitivity reaction 
to abacavir, we performed epicutaneous patch testing with the use of abacavir.
Results
The prevalence of HLA-B*5701 was 5.6% (109 of 1956 patients). Of the patients receiv-
ing abacavir, 72% were men, 84% were white, and 18% had not previously received 
antiretroviral therapy. Screening eliminated immunologically confirmed hypersen-
sitivity reaction (0% in the prospective-screening group vs. 2.7% in the control 
group, P<0.001), with a negative predictive value of 100% and a positive predictive value 
of 47.9%. Hypersensitivity reaction was clinically diagnosed in 93 patients, with a 
significantly lower incidence in the prospective-screening group (3.4%) than in the 
control group (7.8%) (P<0.001).
Conclusions
HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In 
predominantly white populations, similar to the one in this study, 94% of patients 
do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction 
to abacavir. Our results show that a pharmacogenetic test can be used to prevent a 
specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)
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P 
harmacogenetic  testing  is  not 
widely used in routine clinical practice to 
optimize drug choice or clinical manage-
ment.1 This gap between scientific knowledge 
and clinical application may be explained by the 
fact that the successful incorporation of a phar-
macogenetic test into routine practice requires a 
combination of high-level evidence that can be 
generalized  to  diverse  clinical  settings,  wide-
spread availability of cost-effective and reliable 
laboratory tests, and effective strategies to incor-
porate testing into routine clinical practice.
Abacavir is a nucleoside reverse-transcriptase 
inhibitor  with  activity  against  the  human  im-
munodeficiency virus (HIV), available for once-
daily use in combination with other antiretroviral 
agents, that has shown efficacy, few drug inter-
actions, and a favorable long-term toxicity pro-
file. The most important adverse effect of abaca-
vir that limits its use in therapy and mandates a 
high degree of clinical vigilance is an immuno-
logically mediated hypersensitivity reaction affect-
ing 5 to 8% of patients during the first 6 weeks 
of treatment.2,3 Symptoms of a hypersensitivity 
reaction to abacavir include combinations of fever, 
rash, constitutional symptoms, gastrointestinal 
tract symptoms, and respiratory symptoms that 
become more severe with continued dosing. Im-
mediate and permanent discontinuation of abac-
avir is mandated, resulting in a rapid reversal of 
symptoms. Subsequent rechallenge with abacavir 
is contraindicated, since it can result in a more 
severe, rapid, and potentially life-threatening re-
action.2
Symptoms of the hypersensitivity reaction to 
abacavir are nonspecific and can be difficult to 
distinguish from concomitant infection, reaction 
to other drugs, or inflammatory disease. This is 
a problem for phenotyping and can lead to false 
positive clinical diagnoses: in blind, comparative 
trials of regimens involving abacavir, hypersen-
sitivity reaction was reported in 2 to 7% of pa-
tients who were not receiving abacavir.4-6
In 2002, an association between a diagnosis of 
hypersensitivity reaction to abacavir and carriage 
of the major histocompatibility complex class I 
allele HLA-B*5701 was reported independently 
by two research groups7,8 and was subsequently 
corroborated by several independent studies.9-12 
Studies of cohorts with HIV infection have also 
shown that avoiding abacavir in HLA-B*5701–pos-
itive patients significantly reduced the incidence 
of suspected hypersensitivity reaction, as compared 
with prescreening rates in a Western Australian 
cohort13 and historical rates in Brighton, United 
Kingdom,14 and in France.15 Overall, these pro-
spective and retrospective studies have not pro-
vided evidence that is sufficient for the imple-
mentation of HLA-B*5701 screening because of 
limitations such as small numbers of patients stud-
ied, geographic localization, retrospective meth-
ods, lack of a contemporary control population, 
lack of racial diversity, and nonuniform case as-
certainment of hypersensitivity reactions to abac-
avir. Moreover, clinical overdiagnosis has led to a 
substantial overestimation of the prevalence of 
hypersensitivity reaction over the true prevalence 
of immunologically mediated hypersensitivity re-
action. This is particularly true in racial groups 
with a low carriage frequency of HLA-B*5701, in 
which false positive clinical diagnosis has resulted 
in the erroneous conclusion that the test lacks 
sensitivity.10
The use of epicutaneous patch testing addresses 
the problem of false positive clinical diagnosis by 
identifying patients who have had an immunologi-
cally mediated hypersensitivity reaction to aba-
cavir, without the risks associated with systemic 
rechallenge.11,16 A positive patch-test result, mea-
sured by a visible and palpable localized response, 
denotes a delayed hypersensitivity response to 
abacavir in patients for whom previous ingestion 
of the drug (resulting in adequate systemic expo-
sure) has caused immunologic priming to occur. 
For this reason, epicutaneous patch testing cannot 
be used as a predictive screening tool in patients 
who have not previously ingested abacavir. All pa-
tients with a clinical syndrome compatible with 
hypersensitivity to abacavir who were identified as 
having a positive result on epicutaneous patch test-
ing to date have carried HLA-B*5701,9,11,17,18 sup-
porting the robustness of the association between 
HLA-B*5701 and hypersensitivity reaction to aba-
cavir.19 However, not all HLA-B*5701–positive pa-
tients will have a hypersensitivity reaction to aba-
cavir.
The strength of the existing evidence, the avail-
ability of patch testing as a research tool for the 
identification of patients who could have had a 
hypersensitivity reaction, and widespread acknowl-
edgment that definitive prospective data are re-
quired to include HLA-B*5701 screening in the 
standard of care provide the rationale for our 
study. The Prospective Randomized Evaluation 
of DNA Screening in a Clinical Trial (PREDICT-1) 
study is a prospective, randomized, multicenter, 
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double-blind  study  to  determine  whether  the 
screening of adults infected with HIV type 1 
(HIV-1) for HLA-B*5701 before treatment with 
antiretroviral therapy involving abacavir results 
in a significantly reduced incidence of hypersen-
sitivity reaction to abacavir.
Methods
Roles and Contributions
The industry authors and three academic authors 
designed the study and the analyses, with input 
from the other investigators. The data were held 
by the sponsor and shared in full with the aca-
demic authors, and the analyses were performed 
by an industry author and three academic authors. 
The manuscript was written by two academic au-
thors and four industry authors. All the authors 
evaluated the study results, reviewed and edited 
the manuscript, and vouch for the completeness 
and accuracy of the data presented.
Participants
Patients were assessed for eligibility and were ran-
domly assigned to undergo either prospective or 
retrospective HLA-B*5701 testing between April 
and September 2006 at 265 centers in 19 countries. 
Eligible patients were adults with HIV-1 infection 
and a preestablished clinical need for treatment 
with an antiretroviral-drug regimen containing 
abacavir but with an unknown HLA-B*5701 sta-
tus. Patients could not have previously received 
abacavir, but they could have received other anti-
retroviral drugs. All abacavir treatment was given 
in accordance with the recommendations on the 
product label. The study was performed in accor-
dance with the International Conference on Har-
monisation and Good Clinical Practice Standards, 
including approval by the local ethics committee 
at each participating institution and with written 
informed consent from all patients.
Procedures
The study design consisted of a 28-day to 60-day 
evaluation period to determine eligibility and per-
form randomization. Abacavir was initiated in 
eligible patients on day 1 of the study, followed by 
an observation period of 6 weeks (Fig. 1). Eligible 
patients were randomly assigned, in a one-to-one 
ratio, to undergo one of two study approaches: 
prospective HLA-B*5701 pharmacogenetic screen-
ing followed by combination active antiretroviral 
therapy that included abacavir (the prospective-
screening group), or combination active antiretro-
viral therapy that included abacavir, followed by 
retrospective HLA-B*5701 pharmacogenetic screen-
ing (the control group).
Randomization was based on a computer-gen-
erated, centralized schedule, with a block size of 
four and stratification according to self-reported 
race (white vs. nonwhite), history of receipt of an-
tiretroviral therapy (none vs. any), and intention 
to commence a new nonnucleoside reverse-tran-
scriptase inhibitor between the time of the visit 
to assess eligibility and day 1 of the study (the 
first day of abacavir therapy).
Blood samples for use in HLA-B*5701 screen-
ing were collected from all patients during the 
evaluation period. However, only those from pa-
tients who had been randomly assigned to the 
prospective-screening  group  were  subjected  to 
real-time testing for carriage of HLA-B*5701 dur-
ing the evaluation period. Samples from patients 
who had been randomly assigned to the control 
group were retrospectively tested for HLA-B*5701 
at  the  end  of  the  study.  HLA-B*5701–positive 
patients in the prospective-screening group did 
not receive abacavir as part of the study (Fig. 1). 
HLA-B*5701–negative  patients  in  the  prospec-
tive-screening group and all patients in the con-
trol group started the study after receiving noti-
fication of their eligibility to receive abacavir from 
the central study-management group. Investiga-
tors, patients, and the study-management team 
were unaware of the group assignments.
HLA-B*5701 screening was performed with the 
use of DNA-sequence–based typing (at the Centre 
for Clinical Immunology and Biomedical Statistics, 
Royal Perth Hospital, Perth, Western Australia) 
and a sequence-specific oligonucleotide probe 
method (Laboratory Corporation of America), with 
additional DNA sequencing for patients for whom 
the probe results were positive. Patients wishing 
to know their HLA-B*5701 status were notified 
at the end of the study.
Assessments were performed at the time of 
study entry, on day 1 (baseline), and at weeks 1, 
2, and 6. Investigators were trained in relevant 
study procedures during teaching sessions and 
with the use of illustrated guides and an infor-
mational video.
Hypersensitivity reactions to abacavir were di-
agnosed by the principal investigator at the site, 
without the use of predefined clinical criteria. 
Patients receiving this diagnosis stopped taking 
abacavir immediately and permanently, and they 
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1956 Patients were enrolled and randomly
assigned (1:1) to a study group
980 Were assigned to the prospec-
tive-screening group
980 Underwent prospective genetic
screening for HLA-B*5701
55 Were positive for HLA-B*5701
54 Did not receive highly active
antiretroviral therapy
involving abacavir
1 Received highly active anti-
retroviral therapy involving
abacavir in error and was
promptly withdrawn
925 Were negative for HLA-B*5701 
858 Received highly active anti-
retroviral therapy involving 
abacavir
67 Did not receive treatment
24 Withdrew consent
18 Had a protocol violation
15 Were lost to follow-up
3 Were not compliant
3 Had an adverse event
4 Were not treated for other
reasons
976 Were assigned to the control
group
913 Received highly active anti-
retroviral therapy involving
abacavir
63 Did not receive treatment
23 Withdrew consent
9 Had a protocol violation
11 Were lost to follow-up
4 Were not compliant
1 Had an adverse event
9 Were not treated owing
to investigator’s decision
6 Were not treated for
other reasons
803 Could be evaluated for clini-
cally diagnosed hypersensi-
tivity reaction
55 Could not be evaluated
6 Withdrew owing to an
   adverse event other than
   hypersensitivity reaction
5 Were lost to follow-up
4 Withdrew owing to a
   protocol violation
5 Withdrew for personal
   reasons
3 Withdrew owing to
   noncompliance
2 Withdrew for other reasons
27 Had received abacavir for
<41 days
3 Missed the week 6 visit
847 Could be evaluated for clini-
cally diagnosed hypersensi-
tivity reaction
66 Could not be evaluated
15 Withdrew owing to an
     adverse event other than
     hypersensitivity reaction
3 Were lost to follow-up
5 Withdrew owing to a
   protocol violation
5 Withdrew for personal
   reasons
2 Withdrew owing to
   noncompliance
34 Had received abacavir for
<41 days
2 Missed the week 6 visit
802 Could be evaluated for
immunologically confirmed
hypersensitivity reaction
1 Refused patch testing
842 Could be evaluated for
immunologically confirmed
hypersensitivity reaction
5 Could not be evaluated
3 Refused patch testing
1 Was lost to follow-up
1 Did not attend the patch-
test visit
AUTHOR:
FIGURE:
JOB: ISSUE:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Mallal
1 of 1
02-07-08
ARTIST: ts
35806
Figure 1. Enrollment, Randomization, and Follow-up in the Study.
All patients who received abacavir were observed for at least 6 weeks after the therapy was started. All patients  
with suspected hypersensitivity reaction to abacavir were scheduled for epicutaneous patch testing.
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returned to the site as soon as possible for an 
assessment of the hypersensitivity reaction.
All patients with a clinical diagnosis of hyper-
sensitivity  to  abacavir  underwent  epicutaneous 
patch testing 6 to 10 weeks after the onset of the 
reaction, according to a modification of the meth-
od of Phillips et al.11,16 The first 100 patients 
who could tolerate abacavir and who completed 
the study continued to receive abacavir and then 
also underwent epicutaneous patch testing between 
weeks 6 and 10.
The results of patch testing were scored by an 
expert, independent, clinical-evaluation commit-
tee on the basis of digital photographs taken on 
site with cameras provided for use in the study, 
as well as other patch-test information. The com-
mittee was unaware of the clinical history and 
HLA-B*5701 status of all patients. Both the com-
mittee and the investigators performing the epi-
cutaneous patch testing were unaware of the or-
der of application of the test-contact samples 
within the patches.
Study Objective and End Points
The objective of the study was to test the hypoth-
esis that prospective pharmacogenetic screening 
for HLA-B*5701 and the exclusion of those pa-
tients carrying the allele from abacavir treatment 
reduces the incidence of hypersensitivity reaction 
to  abacavir  as  compared  with  that  in  an  un-
screened population. The primary end points were 
the rate of clinically diagnosed hypersensitivity 
reaction to abacavir during the 6-week observa-
tion period and the rate of immunologically con-
firmed hypersensitivity reaction (defined as a clini-
cally diagnosed reaction that was confirmed by a 
positive result on epicutaneous patch testing 6 to 
10 weeks after clinical diagnosis).
Statistical Analysis
The statistical design and power calculations for 
the study have been published previously.20 Brief-
ly, we calculated that we would need to enroll 1578 
patients who could be evaluated (789 per group) 
for the study to have a statistical power of 90% to 
detect a relative reduction in the incidence of clin-
ically diagnosed hypersensitivity reaction to abac-
avir of 50% in the prospective-screening group as 
compared with the control group (7.3% vs. 3.6%), 
with a two-sided significance level of 0.05. This 
number of patients also yielded a statistical power 
of more than 99% to detect a relative reduction of 
80% in the prospective-screening group for im-
munologically confirmed hypersensitivity reaction 
to abacavir (4.6% vs. 0.9%).
Hierarchical testing was used to adjust for the 
multiplicity of primary end points. Rates of clini-
cally  diagnosed  hypersensitivity  reaction  were 
analyzed only if there was a significant difference 
in the rates of immunologically confirmed hyper-
sensitivity reaction between the two study groups.
The primary analysis of the rates of clinically 
diagnosed hypersensitivity reaction involved the 
patients who could be evaluated among all patients 
who received at least one dose of abacavir, defined 
as those who either completed the week-6 visit 
after taking abacavir for at least 41 days with-
out evidence of hypersensitivity reaction or who 
stopped taking abacavir, owing to a clinical di-
agnosis of a hypersensitivity reaction, before or 
during the week-6 visit. The primary analysis of 
rates of immunologically confirmed hypersensi-
tivity reaction involved the same group of patients 
except six who did not undergo epicutaneous patch 
testing because of refusal, failure to appear for 
testing, or loss to follow-up. Potential bias intro-
duced by the exclusion of the patients who could 
not be evaluated was addressed by several sensi-
tivity analyses of data from the full intention-to-
treat population that had received abacavir, with 
assumptions about the missing data ranging from 
0 to 100% of the exclusions being associated with 
a hypersensitivity reaction. The safety population 
for analyses of adverse events and laboratory data 
included all patients who received at least one dose 
of abacavir.
The rates of clinically diagnosed hypersensi-
tivity reaction were compared between the two 
groups by means of logistic-regression analysis, 
with the P value calculated with the use of the 
likelihood-ratio test. Because of the numbers of 
immunologically confirmed hypersensitivity re-
actions reported, exact-logistic-regression analysis 
was performed for that end point, and the median 
unbiased estimate of the odds ratio was calcu-
lated with the use of the mid–P value from the 
score test. A two-sided significance level of 5% was 
used in all comparisons between the study groups. 
Sensitivity, specificity, and positive and negative 
predictive values of HLA-B*5701 for the hyper-
sensitivity reaction to abacavir were calculated 
with the use of data from the control group only.
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Results
A total of 1956 patients were enrolled and ran-
domly assigned to a study group (Fig. 1). Of the 
980 patients in the prospective-screening group, 
55 (5.6%) were excluded from the main study be-
cause they were carriers of the HLA-B*5701 al-
lele. The populations that could be evaluated for 
clinically diagnosed hypersensitivity reaction con-
sisted of 803 patients in the prospective-screen-
ing group and 847 patients in the control group. 
The populations that could be evaluated for im-
munologically confirmed hypersensitivity reaction 
consisted of 802 patients in the prospective-screen-
ing group and 842 patients in the control group.
Baseline characteristics were similar between 
the two study groups (Table 1). Self-reported race 
was white in 1397 of the 1650 patients who could 
be evaluated (84.7%; 679 of the 803 patients in 
the prospective-screening group and 718 of the 
847 patients in the control group). The numbers 
of patients in the other racial or ethnic categories 
were too small to perform subanalyses.
After the exclusion of two patients with missing 
results from one laboratory, there was complete 
concordance between the results of HLA-B*5701 
screening by means of the sequence-specific oli-
gonucleotide probe and DNA sequencing. A total 
of 109 of the 1956 patients (5.6%) carried HLA-
B*5701.
The incidences of immunologically confirmed 
and clinically diagnosed hypersensitivity reaction 
to abacavir were significantly lower in the pro-
spective-screening group than in the control group 
Table 1. Baseline Characteristics of the Study Population That Could Be Evaluated for Clinically Diagnosed 
Hypersensitivity.
Characteristic
Prospective Screening 
(N = 803)
Control  
(N = 847) P Value*
Sex — no. (%) 0.19
Male 595 (74.1) 602 (71.1)
Female 208 (25.9) 245 (28.9)
Age — yr 0.91
Mean 42 42
Range 18–77 18–76
Race or ethnic group — no. (%)† 0.96
White
Caucasian or European ancestry 665 (82.8) 702 (82.9)
Arabic or North African ancestry 12 (1.5) 13 (1.5)
Black 96 (12.0) 96 (11.3)
American Indian or Alaskan native 8 (1.0) 10 (1.2)
Mixed 7 (0.9) 11 (1.3)
Other 14 (1.7) 15 (1.8)
Previous receipt of antiretroviral drugs — no. (%) 0.75
No 147 (18.3) 149 (17.6)
Yes 656 (81.7) 698 (82.4)
Concurrent PI use — no. (%) 358 (44.6) 370 (43.7) 0.75
Introduction of NNRTI after screening — no. (%) 87 (10.8) 79 (9.3) 0.35
* All P values were calculated post hoc. The P value reported for race or ethnic group was calculated for the comparison 
between both subgroups of white patients and all other patients. NNRTI denotes nonnucleoside reverse-transcriptase 
inhibitor, and PI protease inhibitor.
† Race or ethnic group was self-reported. One patient in the prospective-screening group did not provide this informa-
tion. “Other” includes all racial categories for which there were less than 1% of patients in either study group, including 
patients reporting both categories of white ancestry (two in the prospective-screening group and three in the control 
group).
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(immunologically confirmed: odds ratio, 0.03; 95% 
confidence interval [CI], 0.00 to 0.18; P<0.001; 
clinically diagnosed: odds ratio, 0.40; 95% CI, 
0.25 to 0.62; P<0.001). No case of clinically diag-
nosed hypersensitivity reaction in the prospective-
screening group was immunologically confirmed. 
Results were similar for the subgroup of white 
patients (Table 2). Sensitivity analyses involving 
the intention-to-treat, abacavir-exposed population 
also had similar results. When 0% and 100% of 
the exclusions were assumed to have been as-
sociated with hypersensitivity reaction, the odds 
ratios for immunologically confirmed hypersen-
sitivity reaction to abacavir in the prospective-
screening group, as compared with the control 
group, were 0.03 (P<0.001) and 0.62 (P = 0.006), 
respectively,  and  the  odds  ratios  for  clinically 
diagnosed  hypersensitivity  reaction  were  0.40 
(P<0.001) and 0.63 (P = 0.002), respectively.
As shown in Table 3, only prospective screen-
ing was a significantly negative predictor of both 
clinically diagnosed and immunologically con-
firmed hypersensitivity reaction. Only concurrent 
use of an HIV protease inhibitor and introduction 
of a new nonnucleoside reverse-transcriptase in-
hibitor were significant predictors of clinically di-
agnosed hypersensitivity reaction that was not 
immunologically  confirmed.  However,  these 
variables were not significantly associated with 
immunologically confirmed hypersensitivity re-
action.
For immunologically confirmed hypersensitiv-
ity reaction, the HLA-B*5701 allele was associ-
ated with a positive predictive value of 47.9% and 
a negative predictive value of 100%. For clinically 
diagnosed hypersensitivity reaction, the presence 
of the allele had a positive predictive value of 61.2% 
and a negative predictive value of 95.5% (Table 4).
The 100 patients who had clinical tolerance of 
abacavir and then underwent epicutaneous patch 
testing had negative tests, resulting in a speci-
ficity of patch testing of 100% (95% CI, 96.4 to 
100) for clinically diagnosed hypersensitivity re-
action. None of the 100 patients were carriers of 
HLA-B*5701. In all, 61 of the 66 patients in the 
control  group  who  had  clinically  diagnosed 
hypersensitivity reaction also had epicutaneous 
patch-testing results that could be evaluated. Of 
these 61 patients, all 23 patients with a positive 
epicutaneous patch test were HLA-B*5701–posi-
tive, whereas 32 of 38 with a negative epicutane-
ous patch test were HLA-B*5701–negative (with 
the remaining 6 being HLA-B*5701–positive).
A total of 665 of 1772 patients exposed to 
Table 2. Incidence of Hypersensitivity Reaction to Abacavir.*
Hypersensitivity Reaction
Prospective 
Screening Control
Odds Ratio  
(95% CI)* P Value
no. of patients/total no. (%)
Clinically diagnosed
Total population that could be evaluated 27/803 (3.4) 66/847 (7.8) 0.40 (0.25–0.62) P<0.001
White subgroup 24/679 (3.5) 61/718 (8.5) 0.38 (0.23–0.62) P<0.001
Immunologically confirmed
Total population that could be evaluated 0/802 23/842 (2.7) 0.03 (0.00–0.18) P<0.001
White subgroup 0/679 22/713 (3.1) 0.03 (0.00–0.19) P<0.001
* P values, odds ratios, and 95% confidence intervals (CIs) were calculated by means of logistic-regression analysis and 
adjusted for self-reported race (white vs. nonwhite), history of receipt of antiretroviral therapy (none vs. any), introduc-
tion of a new nonnucleoside reverse-transcriptase inhibitor (yes or no), and concurrent use or nonuse of a protease in-
hibitor. The model-based incidences of clinically diagnosed hypersensitivity reaction to abacavir in the total population 
that could be evaluated and in the white subgroup were 3.3% and 3.5%, respectively, for the prospective-screening 
group and 7.9% and 8.6%, respectively, for the control group. The white subgroup included the two and three patients 
reporting both categories of white ancestry in the prospective-screening group and the control group, respectively. The 
odds ratios for immunologically confirmed hypersensitivity reaction to abacavir were obtained by means of exact meth-
ods, owing to the absence of immunologically confirmed hypersensitivity reaction in the prospective-screening group. 
The model (involving a median, unbiased estimate of the odds ratio) estimated the odds of hypersensitivity reaction in 
the prospective-screening group versus the control group to be 1:33 (1 ÷ 0.03 = 33). (Although a simple point estimate 
of the odds ratio from the raw data yields a more intuitive value of 0, it also implies an infinite reduction in the odds, 
which is problematic for linear regression modeling in that it introduces error from division by 0.)
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abacavir (37.5%) for whom the data were avail-
able reported an adverse event. Grade 1 adverse 
events only were reported in 355 of the 665 pa-
tients (53.4%), and 246 of the 665 patients (37.0%) 
were considered to have had an event related to 
the use of abacavir. The only events of grade 2, 3, 
or 4, reported in more than 1% of the study popu-
lation, were drug hypersensitivity (in 79 of 1772 
patients [4.5%]) and diarrhea (in 32 of 1772 pa-
tients [1.8%]). A total of 119 of 1772 patients 
(6.7%)  were  reported  to  have  serious  adverse 
events, of which the majority (in 97 of 119 pa-
tients [81.5%]) were considered to be related to 
abacavir therapy. Almost all the serious abacavir-
related events (in 93 of 97 patients [95.9%]) were 
hypersensitivity reactions, which were reported 
as serious adverse events regardless of their se-
verity.
The reported symptoms of hypersensitivity re-
action to abacavir in our study included fever, rash, 
gastrointestinal disturbances, and constitutional 
symptoms (e.g., tachycardia, hypotension, myal-
gia, fatigue, pain, malaise, dizziness, and head-
ache), findings that are consistent with those pre-
viously reported. The median time to the onset 
of symptoms was 10 days (interquartile range,   
3 to 14) in the prospective-screening group and 
9 days (interquartile range, 5 to 12) in the control 
group. For the immunologically confirmed hyper-
sensitivity reaction in the control group, the me-
dian time to the onset of symptoms was 8 days 
(interquartile range, 5 to 10). All symptoms of 
hypersensitivity reaction improved quickly after 
the withdrawal of abacavir, with no sequelae. In 
addition, all five patients with clinically diag-
nosed hypersensitivity reactions occurring after 
day 21 had negative results on epicutaneous patch 
testing.
Table 3. Results of Multivariate Analysis for Covariates Potentially Associated with Hypersensitivity to Abacavir.*
Covariate
Clinically Diagnosed 
Hypersensitivity  
Reaction
Immunologically  
Confirmed  
Hypersensitivity  
Reaction
Clinically  
Diagnosed but Not  
Immunologically 
Confirmed  
Hypersensitivity  
Reaction
Prospective screening, vs. control
Odds ratio (95% CI) 0.40 (0.25–0.62) 0.03 (0.00–0.18) 0.69 (0.41–1.14)
P value P<0.001 P<0.001 P = 0.15
White race, vs. nonwhite
Odds ratio (95% CI) 2.19 (1.10–5.01) 4.21 (0.67–175.5) 2.00 (0.91–5.27)
P value P = 0.02 P = 0.11 P = 0.09
No previous receipt of antiretroviral drugs, vs. any
Odds ratio (95% CI) 1.37 (0.79–2.32) 1.20 (0.31–3.82) 1.49 (0.78–2.73)
P value P = 0.26 P = 0.66 P = 0.22
Introduction of NNRTI, vs. no introduction
Odds ratio (95% CI) 3.19 (1.61–6.18) 1.45 (0.22–6.49) 4.04 (1.82–8.83)
P value P = 0.001 P = 0.57 P<0.001
Concurrent PI use, vs. no concurrent use
Odds ratio (95% CI) 1.86 (1.16–3.01) 1.05 (0.39–2.79) 2.38 (1.33–4.39)
P value P = 0.009 P = 0.91 P = 0.003
* Before analysis of the primary end points, we performed stepwise regression analysis of potentially important covari-
ates for the prediction of clinically suspected hypersensitivity reaction. The three randomization strata (which were 
forced to remain in the model) and other additional factors retained (listed above) were then included in the analyses 
of the primary end points. The additional factors were sex, Centers for Disease Control and Prevention class, HIV RNA 
level at baseline, CD4+ cell count at baseline, once-daily or twice-daily abacavir dosing, and concurrent use or nonuse 
of a protease inhibitor (PI). For the analysis of immunologically confirmed hypersensitivity reaction, the same covari-
ates were used as those found to be important for clinically diagnosed hypersensitivity reaction. NNRTI denotes non-
nucleoside reverse-transcriptase inhibitor.
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Discussion
The results of the PREDICT-1 study show that pro-
spective HLA-B*5701 screening can reduce the 
incidence of hypersensitivity reaction to abacavir 
(Table 2). In our study, prospectively excluding 
HLA-B*5701–positive patients from receiving aba-
cavir eliminated immunologically confirmed hy-
persensitivity reaction and significantly reduced 
the rate of diagnosis of clinical hypersensitivity 
reaction. HLA-B*5701 carriage clearly demarcated a 
high-risk group of patients, accounting for approx-
imately 6% of the population, from the remain-
ing 94% who were at low risk for a hypersensitiv-
ity reaction to abacavir.
The double-blind design of the PREDICT-1 study 
meant that HLA-B*5701 status could not be con-
sidered in evaluating the symptoms that resulted 
in a diagnosis of hypersensitivity reaction. This 
strengthens our findings, by ensuring that equiv-
alent clinical vigilance and diagnostic criteria were 
used in the assessment of the patients who re-
ceived  abacavir  in  both  groups.  However,  the 
double-blind design also means that we could not 
address  the  potential  benefits  of  HLA-B*5701 
screening observed in open-screening studies in 
the clinic, such as a decrease in the rate of false 
positive clinical diagnoses of hypersensitivity re-
action  in  patients  known  to  be  HLA-B*5701–
negative.13-15
The 3.4% rate of clinically diagnosed hyper-
sensitivity reaction that was not immunologically 
confirmed in the prospective-screening group is 
similar to the false positive rates of hypersensi-
tivity reaction (2 to 7%) among patients not receiv-
ing abacavir in double-blind comparative-treat-
ment studies.4-6,21 Moreover, the concomitant 
use of a protease inhibitor and initiation of a 
Table 4. Performance Characteristics of HLA-B*5701 Screening for Hypersensitivity Reaction to Abacavir in the Control Group.*
Subgroup
Positive for  
HLA-B*5701
Negative for  
HLA-B*5701 Total
Performance Characteristic  
for Hypersensitivity Reaction 
number of patients percent (95% CI)
Clinically diagnosed hypersensitivity reaction
Total population that could be evaluated
Hypersensitivity reaction 30 36 66 Sensitivity: 45.5 (33.1–58.2)
No hypersensitivity reaction 19 762 781 Specificity: 97.6 (96.2–98.5)
PPV: 61.2 (46.2–74.8)
NPV: 95.5 (93.8–96.8)
White subgroup
Hypersensitivity reaction 29 32 61 Sensitivity: 47.5 (34.6–60.7)
No hypersensitivity reaction 19 638 657 Specificity: 97.1 (95.5–98.3)
PPV: 60.4 (45.3–74.2)
NPV: 95.2 (93.3–96.7)
Immunologically confirmed hypersensitivity reaction
Total population that could be evaluated
Hypersensitivity reaction 23 0 23 Sensitivity: 100 (85.2–100)
No hypersensitivity reaction 25 794 819 Specificity: 96.9 (95.5–98.0)
PPV: 47.9 (33.3–62.8)
NPV: 100 (99.5–100)
White subgroup
Hypersensitivity reaction 22 0 22 Sensitivity: 100 (84.6–100)
No hypersensitivity reaction 25 666 691 Specificity: 96.4 (94.7–97.6)
PPV: 46.8 (32.1–61.9)
NPV: 100 (99.4–100)
* The white subgroup included the two and three patients reporting both categories of white ancestry in the prospective-screening group and 
the control group, respectively. NPV denotes negative predictive value, and PPV positive predictive value.
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new nonnucleoside reverse-transcriptase inhibi-
tor were the only significant predictors of clini-
cally diagnosed but not immunologically con-
firmed  hypersensitivity  reaction  in  our  study 
(Table 3). This result indicates that symptoms such 
as rash associated with efavirenz,22 hypersensi-
tivity reaction (fever, rash, or hepatitis) associated 
with nevirapine,23 or gastrointestinal symptoms 
associated with an HIV protease inhibitor con-
tributed to diagnoses of hypersensitivity reaction 
to abacavir that were not immunologically con-
firmed.
Although  a  positive  result  of  epicutaneous 
patch testing in our study indicates a true, im-
munologically mediated hypersensitivity reaction 
to abacavir, a negative result can neither rule out 
this diagnosis nor be used to justify rechallenge 
with abacavir. The fact that six HLA-B*5701–pos-
itive patients had clinically diagnosed hypersen-
sitivity reaction to abacavir but negative results of 
epicutaneous patch tests may have been due to a 
false positive clinical diagnosis of hypersensitiv-
ity reaction or a false negative result of patch test-
ing from either operator error or host factors.
As in other studies, all patients with a posi-
tive epicutaneous patch test carried HLA-B*5701, 
providing further evidence that the HLA-B*5701 
test has a high sensitivity (perhaps 100%) for 
immunologically confirmed hypersensitivity reac-
tion.9,11,17,18 Clinical diagnosis, on the other hand, 
is most reliable for identifying patients who have 
tolerance of abacavir. Thus, immunologically con-
firmed hypersensitivity reaction provides the best 
estimate of sensitivity (100% in our study), where-
as clinical diagnosis provides the best estimate of 
specificity (97.6%). Given these estimates and the 
5.6% carriage frequency of HLA-B*5701 in our 
study, the overall estimated positive and negative 
predictive values of HLA-B*5701 testing for hyper-
sensitivity reaction to abacavir in this population 
are 58% and 100%, respectively.
The fact that 19 of 49 HLA-B*5701 carriers 
(38.8%) in the control group tolerated abacavir 
during the 6-week observation period without 
evidence of hypersensitivity reaction is consistent 
with previous evidence from ex vivo studies that 
abacavir  stimulates  an  antigen-specific  HLA-
B*5701–restricted CD8+ T-cell response and that 
HLA-B*5701 is necessary, but not sufficient by 
itself, for a hypersensitivity reaction.9,11 Howev-
er, the clinical value of prospective HLA-B*5701 
screening is to identify patients at greatest risk 
rather than to predict which patients will defi-
nitely have a hypersensitivity reaction. In a pop-
ulation similar to that in the PREDICT-1 study, 
with an approximate HLA-B*5701 carriage fre-
quency of 6%, the screening of 100 patients would 
prevent approximately four diagnoses of hyper-
sensitivity while ruling out the use of abacavir in 
two HLA-B*5701–positive patients who would have 
tolerated the drug.
Although  the  population  in  the  PREDICT-1 
study was predominantly white, the association 
between HLA-B*5701 and hypersensitivity reac-
tion to abacavir appears to be generalizable across 
racial groups. A recent retrospective, case–control 
study in the United States showed 100% sensitiv-
ity of HLA-B*5701 carriage for immunologically 
confirmed hypersensitivity in both white patients 
and black patients.17 Furthermore, the presence 
of HLA-B*5701 is associated with clinically diag-
nosed hypersensitivity reaction in Hispanic and 
Thai patients infected with HIV.10,24 Prospective 
HLA-B*5701 screening, as shown in the PREDICT-1 
study, may therefore be broadly useful, although 
the cost-effectiveness of the test will depend on 
several estimates that vary among populations and 
health care settings as well as the availability of 
appropriate laboratory assays.25-27
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